Status:
UNKNOWN
Comprehensive Assessment of Risks for Miscarriage.
Lead Sponsor:
Orthogyn Medical Center, Bulgaria
Conditions:
Spontaneous Abortion
Eligibility:
FEMALE
18-50 years
Brief Summary
This study aims to determine the role of serum biomarkers and placental bloodflow in the comprehensive evaluation of the risk for spontaneous abortion
Detailed Description
To study the added value (if any) of combining serum markers, immunologic factors, and ultrasound parameters in comprehensively evaluating the risk for spontaneous abortion.
Eligibility Criteria
Inclusion
- visualized fetal structures in utero \& heart pulsations until 8th week of gestation
- normal THS/T4 levels
- no uterine malformations
- BMI \< 27
- signed informed consent
Exclusion
- fetal structures in utero \& heart pulsations not visualized until the 8th week of gestation
- elevated THS/T4 levels
- uterine malformations
- BMI \> 27
Key Trial Info
Start Date :
June 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04456660
Start Date
June 20 2020
End Date
December 1 2023
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Orthogyn Medical and Dental Center
Sofia, Bulgaria, 1618